Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

Dependable recurring dividends from quality, high-yield stocks like these five are a recipe for passive income success.

IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after deciding to halt further development of a program relating to its autoimmunity-drug pipeline, sending its stock down 69% in ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Bristol Myers Squibb (BMY) concluded the recent trading session at $56.81, signifying a -0.58% move from its prior day's close.

Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate ...

Drugmakers have greeted 2025, implementing price hikes for 583 products within the first two days of the new year, according ...

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.

Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes and sells ...